AI-Designed Drug Rentosertib May Slow Biological Aging

A mid-stage clinical study conducted by biotech firm Insilico Medicine suggests that rentosertib, a drug developed using generative AI, may slow biological aging. The findings, published in Nature Biotechnology, indicate a significant reduction in predicted biological age for patients receiving the drug compared to a placebo group.

The study analyzed serum proteome profiles from 42 participants suffering from idiopathic pulmonary fibrosis (IPF), the condition rentosertib was originally designed to treat. To ensure the accuracy of the results, researchers employed six independent proteomic aging clocks to verify the reduction in biological age. The drug specifically targets the TNIK (TRAF2 and NCK-interacting protein kinase) protein, which Insilico's PandaOmics AI platform identified as a gene involved in six hallmarks of aging.

The Shift Toward Longevity Science

This research, led by Alex Zhavoronkov of Insilico Medicine, reflects a broader strategic shift within biotechnology and Silicon Valley. Rather than focusing solely on treating individual chronic illnesses, there is a growing movement—supported by high-profile investors such as Jeff Bezos via Altos Labs—to target the fundamental biological aging process itself. By combining AI with cellular reprogramming, these efforts aim to address the root cause of senescence rather than managing the symptoms of age-related decline.

Implications for Public Health

If these results are validated in larger cohorts, the discovery represents a major breakthrough in longevity science. It demonstrates that AI can not only rapidly discover novel drug targets and designs but can also measurably influence biological aging markers in human subjects. Such a capability could potentially reduce the overall incidence of age-related diseases, including heart disease, cancer, and Alzheimer's, by slowing the systemic degradation of the body.

Next Steps for Rentosertib

While the proteomic data is promising, rentosertib must still pass rigorous regulatory hurdles. The drug has already entered Phase III clinical trials in China, where it is enrolling approximately 320 patients across 47 centers. Future analysis will determine if the biological age reversal observed in the mid-stage study translates into improved clinical outcomes and extended healthspans for the general population.